Atazanavir is FDA approved for treating HIV-1 infection, in combination with other antiretroviral agents, for patients who are 3-months-old or older, weighing 5 or more kilograms. It is in the protease inhibitor class of HIV-1 medications. This activity will highlight the indications, mechanism of action, administration, adverse effects, contraindications, and monitoring for atazanavir pertinent for healthcare team members in the management of patients with HIV/AIDS.

**Objectives:**
- Summarize the pharmacokinetics and pharmacodynamics of atazanavir.
- Describe the potential adverse effects of atazanavir.
- Explain appropriate monitoring strategies to identify potential atazanavir toxicity in patients.
- Outline the importance of communication and coordination of care among the interprofessional team and how it can enhance patient care when monitoring atazanavir treatment to improve HIV/AIDS patient outcomes.